These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30253290)

  • 1. The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies.
    Di Minno MND; Scalera A; Tufano A; Ambrosino P; Bettiol A; Silvestri E; Emmi G; Prisco D
    Atherosclerosis; 2018 Nov; 278():60-65. PubMed ID: 30253290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.
    Radin M; Sciascia S; Erkan D; Pengo V; Tektonidou MG; Ugarte A; Meroni P; Ji L; Belmont HM; Cohen H; Ramires de Jesús G; Branch DW; Fortin PR; Andreoli L; Petri M; Rodriguez E; Rodriguez-Pinto I; Knight JS; Atsumi T; Willis R; Gonzalez E; Lopez-Pedrera R; Rossi Gandara AP; Borges Gualhardo Vendramini M; Banzato A; Sevim E; Barbhaiya M; Efthymiou M; Mackie I; Bertolaccini ML; Andrade D;
    Semin Arthritis Rheum; 2019 Dec; 49(3):464-468. PubMed ID: 31153708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction.
    Radin M; Schreiber K; Costanzo P; Cecchi I; Roccatello D; Baldovino S; Bazzan M; Cuadrado MJ; Sciascia S
    Int J Cardiol; 2017 Aug; 240():72-77. PubMed ID: 28385357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina.
    Garcia L; Velloso MS; Martire MV; Savy F; Arizpe F; Garcia N; Testi A; Pena C; Costi AC; Isnardi C; Capelusnik D; Mazza S; Curi YS; Collado V; Rodriguez MF; Scarafia S; Pisoni C; de la Torre M; Seewald A; Riva ME; Garcia M
    Lupus; 2020 Dec; 29(14):1866-1872. PubMed ID: 33028177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic risk assessment in patients with systemic lupus erythematosus: Validation of the adjusted-Global Antiphospholipid Syndrome Score (aGAPSS) in Thai patients.
    Chanloung W; Kasitanon N; Wichainun R; Louthrenoo W
    Int J Rheum Dis; 2021 Dec; 24(12):1510-1519. PubMed ID: 34716670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.
    Uludağ Ö; Bektaş M; Çene E; Sezer M; Şahinkaya Y; Gül A; Inanç M; Öcal L; Artim-Esen B
    J Thromb Thrombolysis; 2021 Feb; 51(2):466-474. PubMed ID: 32588289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome.
    Udry S; Peréz SM; Belizna C; Aranda F; Esteve-Valverde E; Wingeyer SP; Fernández-Romero DS; Latino JO; de Larrañaga G; Alijotas-Reig J
    Lupus; 2022 Mar; 31(3):354-362. PubMed ID: 35157809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management.
    Radin M; Ugolini-Lopes MR; Sciascia S; Andrade D
    Semin Arthritis Rheum; 2018 Aug; 48(1):117-120. PubMed ID: 29395258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis.
    Sciascia S; Radin M; Sanna G; Cecchi I; Roccatello D; Bertolaccini ML
    Rheumatology (Oxford); 2018 Apr; 57(4):661-665. PubMed ID: 29342292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study.
    Del Barrio-Longarela S; Martínez-Taboada VM; Blanco-Olavarri P; Merino A; Riancho-Zarrabeitia L; Comins-Boo A; López-Hoyos M; Hernández JL
    Clin Rev Allergy Immunol; 2022 Oct; 63(2):297-310. PubMed ID: 34910282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head.
    Barinotti A; Radin M; Cecchi I; Foddai SG; Arbrile M; Rubini E; Menegatti E; Roccatello D; Sciascia S
    Int J Cardiol; 2022 Sep; 363():185-189. PubMed ID: 35714714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome.
    Song X; Fan Y; Jia Y; Li G; Liu M; Xu Y; Zhang J; Li C
    Front Immunol; 2022; 13():930087. PubMed ID: 35967319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion.
    Hernández JL; Napal JJ; Icardo M; Bores PG; Pérez-Montes R; Cerveró A; Salmón Z; Olmos JM; Martínez-Taboada VM
    Thromb Res; 2023 Jan; 221():113-119. PubMed ID: 36525919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study.
    Radin M; Schreiber K; Cecchi I; Roccatello D; Cuadrado MJ; Sciascia S
    Eur J Neurol; 2018 Feb; 25(2):320-325. PubMed ID: 29082583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent validation of the adjusted GAPSS: Role of thrombotic risk assessment in the real-life setting.
    Fernandez Mosteirin N; Saez Comet L; Salvador Osuna C; Calvo Villas JM; Velilla Marco J
    Lupus; 2017 Oct; 26(12):1328-1332. PubMed ID: 28387637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome.
    Rodríguez-Sanz A; Martínez-Sánchez P; Prefasi D; Fuentes B; Pascual-Salcedo D; Blanco-Bañares MJ; Díez-Tejedor E
    Autoimmunity; 2015; 48(5):275-81. PubMed ID: 25434364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The systemic nature of the antiphospholipid syndrome.
    Marai I; Zandman-Goddard G; Shoenfeld Y
    Scand J Rheumatol; 2004; 33(6):365-72. PubMed ID: 15794193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical manifestations and thrombotic risk factors in primary antiphospholipid syndrome].
    Zhao JL; Sun YD; Zhang Y; Xu D; Wang Q; Li MT; Zeng XF
    Zhonghua Nei Ke Za Zhi; 2016 May; 55(5):386-91. PubMed ID: 27143190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor 15 (GDF-15) as potential cardiovascular risk biomarker in antiphospholipid syndrome.
    Tektonidou MG; Papassotiriou I; Sfikakis PP
    Rheumatology (Oxford); 2021 Dec; 61(1):394-399. PubMed ID: 33748838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
    Pengo V; Ruffatti A; Legnani C; Gresele P; Barcellona D; Erba N; Testa S; Marongiu F; Bison E; Denas G; Banzato A; Padayattil Jose S; Iliceto S
    J Thromb Haemost; 2010 Feb; 8(2):237-42. PubMed ID: 19874470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.